News

The agreement grants Nutrition 21 an exclusive license in the US and Canada for Coldizin, an ingredient combination, patented in the US and Europe, for enhancing upper-respiratory health.

Targacept has posted a net income of $2.49m for the third quarter 2010, or $0.08 per diluted share, compared to $1.33m, or $0.05 per diluted share, for the

Senesco president and CEO Leslie Browne said that they are pleased to receive this grant to support continued development of SNS01-T, company’s lead therapeutic candidate for the treatment

Fuhrer has over 12 years experience directing teams of scientists and technicians in large pharmaceutical companies, biotech organisations and CROs. Fuhrer has experience in therapeutic areas like anti-infectives,

bitop’s present clinical study is a single-center efficacy and feasibility study involving patients with inflammation and airway obstruction in Germany. bitop said that after the successful feasibility a

Headquartered in Tampa, Florida, Biovest International, in collaboration with the National Cancer Institute, has developed a patient-specific, cancer vaccine, BiovaxID, with three clinical trials completed, including a Phase

The grants, which target therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent or treat

NitroMist is NovaDel’s oral spray formulation of nitroglycerin, which has been approved by the FDA for acute relief of an attack of angina pectoris, or acute prophylaxis of

Emergent posted a net income of $13.12m for the third quarter 2010, or $0.41 per diluted share, compared to net loss of $3.95m, or $0.03 per diluted share,